FrancophonIA/ELRC3.0 huggingface dataset:
English: Slovak Republic
Slovenian: Slovaška
English: Staporos solution for injection in pre-filled syringe intramuscular use, intravenous use, subcutaneous use
Slovenian: Staporos raztopina za injiciranje v napolnjeni injekcijski brizgi intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: Staporos solution for injection intramuscular use, intravenous use, subcutaneous use
Slovenian: Staporos raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: Cadens solution for injection intramuscular use, intravenous use, subcutaneous use
Slovenian: Cadens raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: Calcitonin 'Novartis' 200 I.E. - Nasalspray
Slovenian: Calcitonin 'Novartis' 200 I.E. - Nasalspray pršilo za nos, raztopina nazalna uporaba
English: CALCITONINA SANDOZ 100 UI/ml solution for injection and infusion intravenous use, intramuscular use, subcutaneous use
Slovenian: CALCITONINA SANDOZ 100 i.e./ml raztopina za injiciranje in infundiranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
English: Calsyn solution for injection intramuscular use, intravenous use, subcutaneous use
Slovenian: Calsyn raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: 50 IU/1ML AMP solution for injection intravenous use, intramuscular use, subcutaneous use
Slovenian: 50 i.e./1 ml amp raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
English: Miacalcic solution for injection subcutaneous use, intramuscular use
Slovenian: Miacalcic raztopina za injiciranje subkutana uporaba, intramuskularna uporaba
English: solution for injection intravenous use, intramuscular use, subcutaneous use
Slovenian: raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
English: Miacalcic 100 IU/ml Ampoules solution for injection subcutaneous use, intramuscular use, intravenous use
Slovenian: Miacalcic 100 IU/ml Ampoules raztopina za injiciranje subkutana uporaba, intramuskularna uporaba, intravenska uporaba
English: solution for injection intramuscular use, subcutaneous use
Slovenian: raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
English: 100 IU/1ML AMP solution for injection intravenous use, intramuscular use, subcutaneous use
Slovenian: 100 i.e./1 ML amp raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
English: Miacalcic solution for injection/infusion intramuscular use, intravenous use, subcutaneous use
Slovenian: Miacalcic raztopina za injiciranje/infundiranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: solution for Injection/infusion intramuscular use, subcutaneous use
Slovenian: raztopina za injiciranje/infundiranje intramuskularna uporaba, subkutana uporaba
English: Miacalcic solution for injection intramuscular use, intravenous use, subcutaneous use
Slovenian: Miacalcic raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: Calcitonin 'Novartis' 100 I.E. - Nasalspray
Slovenian: Calcitonin 'Novartis' 100 I.E. - Nasalspray pršilo za nos, raztopina nazalna uporaba
English: solution for injection intramuscular use, intravenous use, subcutaneous use
Slovenian: raztopina za injiciranje intramuskularna uporaba, intravenska uporaba, subkutana uporaba
English: 100 IU/1ML AMP solution for injection intramuscular use, subcutaneous use
Slovenian: 100 i.e./1 ml amp raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
English: 200UI/1d.
Slovenian: 200 i.e.
English: 100 IU
Slovenian: 100 i.e.
English: Miacalcic solution for injection intramuscular use, subcutaneous use
Slovenian: Miacalcic raztopina za injiciranje intramuskularna uporaba, subkutana uporaba
English: Miacalcic solution for injection/infusion subcutaneous use, intramuscular use
Slovenian: Miacalcic raztopina za injiciranje/infundiranje subkutana uporaba, intramuskularna uporaba
English: Miacalcic Nasal 200 200 IU/dose nasal spray nasal use
Slovenian: Miacalcic Nasal 200 200 i.e./odmerek pršilo za nos nazalna uporaba
English: 50 IU
Slovenian: 50 i.e.
English: Miacalcic solution for injection/infusion intramuscular use, subcutaneous use
Slovenian: Miacalcic raztopina za injiciranje/infundiranje intramuskularna uporaba, subkutana uporaba
English: Calcitonin Stada 100 I.E. Injektionslösung 100 IU / 1 ml solution for injection intravenous use, intramuscular use, subcutaneous use
Slovenian: Calcitonin Stada 100 I.E. Injektionslösung raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
English: Miacalcic solution for injection intravenous use subcutaneous use, intramuscular use
Slovenian: Miacalcic raztopina za injiciranje intravenska uporaba, subkutana uporaba, intramuskularna uporaba
English: 100 i.e./ml solution for injection/infusion subcutaneous use, intramuscular use, intravenous use
Slovenian: 100 i.e./1 ml amp raztopina za injiciranje intravenska uporaba, intramuskularna uporaba, subkutana uporaba
English: blister (alu/alu)
Slovenian: pretisni omot (alu/alu)
English: Pack size bottle (HDPE)
Slovenian: Velikost pakiranja plastenka (HDPE)
English: Route of Administration
Slovenian: Pot uporabe
English: EU Number
Slovenian: Številka EU
English: Route of Administration vial (glass)
Slovenian: Viala (steklo)
English: Strength Pharmaceutical Form
Slovenian: Izmišljeno ime Jakost Farmacevtska oblika
English: Medicinal Product no longer authorised
Slovenian: Zdravilo nima veā dovoljenja za promet
English: 1 pre-filled syringe with needleguard + 1 alcohol pad
Slovenian: 1 napolnjena injekcijska brizga s ščitnikom za iglo + 1 alkoholni zloženec
English: 1 vial + 1 syringe + 2 alcohol pads
Slovenian: 1 injekcijska brizga + 2 alkoholna zloženca
English: 1 pre-filled syringe + 1 alcohol pad
Slovenian: 6 napolnjenih injekcijskih peresnikov + 6 alkoholnih zložencev
English: In doubtful cases, patients should be referred to a neurologist for appropriate investigations.
Slovenian: V dvomljivih primerih je treba bolnike napotiti k nevrologu za izvedbo ustreznih preiskav.
English: Children and adolescents <invented name> is not recommended in children aged below 18 years.
Slovenian: Otroci in mladostniki Zdravilo <Izmišljeno ime> ni priporočeno pri otrocih, starih do 18 let.
English: Anti-ischemic effects are achieved without concomitant haemodynamic effects.
Slovenian: Protiishemični učinki so doseženi brez sočasnega hemodinamičnega učinka.
English: The majority of the patients recovered within 4 months after trimetazidine withdrawal.
Slovenian: Večina bolnikov je v štirih mesecih po prenehanju jemanja trimetazidina okrevala.
English: Paediatric population:
Slovenian: Pediatrična populacija:
English: A significant difference was also evidenced for the time to onset of angina pectoris (p=0.049).
Slovenian: Značilna razlika je bila dokazana tudi za čas do nastopa angine pektoris (p=0,049).
English: How to take <invented name>
Slovenian: Kako jemati zdravilo <Izmišljeno ime>
English: These cases have a low incidence and are usually reversible after treatment discontinuation.
Slovenian: Prevalenca teh primerov je nizka in običajno so reverzibilni po ukinitvi zdravljenja.
English: If parkinsonian symptoms persist more than 4 months after drug discontinuation, a neurologist opinion should be sought.
Slovenian: Če so simptomi Parkinsonove bolezni prisotni več kot štiri mesece po prenehanju jemanja zdravila, je treba pridobiti mnenje nevrologa.
English: The safety and efficacy of trimetazidine in children aged below 18 years have not been established.
Slovenian: Varnost in učinkovitost trimetazidina pri otrocih, starih do 18 let, še nista bili dokazani.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Slovenian: Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
English: A. Summary of Products Characteristics
Slovenian: A. Povzetek glavnih značilnosti zdravila
English: 4.8 Undesirable effects [the wording below should be inserted]
Slovenian: 4.8 Neželeni učinki [vstaviti je treba naslednje besedilo]
English: Elderly patients
Slovenian: Starejši bolniki:
English: Annex III Amendments to relevant sections of the summary of product characteristics and package leaflet
Slovenian: Priloga III Dopolnitve ustreznih poglavij povzetka glavnih značilnosti zdravila in navodila za uporabo
English: [the wording below should be inserted in the relevant sections]
Slovenian: [spodnje besedilo je treba vstaviti v ustrezna poglavja]
English: Trimetazidine does not have haemodynamic effects in clinical studies, however cases of dizziness and drowsiness have been observed in post-marketing experience (see section 4.8), which may affect ability to drive and use machines.
Slovenian: Trimetazidin v kliničnih študijah ni imel hemodinamičnih učinkov, so pa v času po prihodu zdravila na trg opazili primere omotice in zaspanosti (glejte poglavje 4.8), ki lahko vplivata na sposobnost vožnje in upravljanja s stroji.
English: Caution should be exercised when prescribing trimetazidine to patients in whom an increased exposure is expected: - moderate renal impairment (see sections 4.2 and 5.2), - elderly patients older than 75 years old (see section 4.2)
Slovenian: Pri predpisovanju zdravila bolnikom, pri katerih je predvidena povečana izpostavljenost trimetazidinu, je potrebna previdnost: - z zmerno ledvično okvaro (glejte poglavji 4.2 in 5.2); - starejšim bolnikom, starim nad 75 let (glejte poglavje 4.2).
English: Falls may occur, related to gait instability or hypotension, in particular in patients taking antihypertensive treatment (see section 4.8).
Slovenian: Lahko se pojavijo padci, povezani z nestabilno hojo ali hipotenzijo, zlasti pri bolnikih, zdravljenih z antihipertenzivi (glejte poglavje 4.8).
English: Clinical studies have demonstrated the efficacy and safety of trimetazidine in the treatment of patients with chronic angina, either alone or when the benefit from other antianginal medicinal products was insufficient.
Slovenian: Klinične študije so dokazale učinkovitost in varnost trimetazidina pri zdravljenju bolnikov s kronično angino pektoris, bodisi kot samostojnega zdravila ali ko je bilo zdravljenje z drugimi antianginoznimi zdravili nezadostno.
English: In an ischaemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in the β-oxidation process.
Slovenian: V ishemični celici pridobivanje energije z oksidacijo glukoze zahteva manjšo porabo kisika kot z -oksidacijo.
English: Always take this medicine exactly as your doctor has told you.
Slovenian: Pri jemanju tega zdravila natančno upoštevajte navodila svojega zdravnika.
English: [the currently approved indications should be deleted and replaced by the following]
Slovenian: [trenutno odobrene indikacije je treba izbrisati ter jih nadomestiti z naslednjo]
English: Dose titration in elderly patients should be exercised with caution (see section 4.4).
Slovenian: Prilagoditev odmerka je pri starejših bolnikih treba opraviti s previdnostjo (glejte poglavje 4.4).
English: This medicine may make you feel dizzy and drowsy that may affect your ability to drive or use machinery.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev To zdravilo lahko povzroči omotico ali zaspanost, ki lahko vplivata na vašo sposobnost vožnje in upravljanja strojev.
English: Trimetazidine inhibits β-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation.
Slovenian: Trimetazidin zavira -oksidacijo maščobnih kislin preko zaviranja dolgoverižne-3-ketoacil-CoA tiolaze, kar posledično poveča oksidacijo glukoze.
English: Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia.
Slovenian: Okrepitev oksidacije glukoze optimira energijske procese v celici, s čimer se v času ishemije ohranja ustrezna presnova energije.
English: In the overall population, including both asymptomatic and symptomatic patients, trimetazidine failed to demonstrate a benefit on both ergometric (total exercise duration, time to onset of 1mm ST and time to onset angina) and clinical endpoints.
Slovenian: Pri celotni populaciji, ki je vključevala asimptomatske in simptomatske bolnike, niso uspeli dokazati prednosti trimetazidina niti pri ergometričnih (trajanje celotne vadbe, čas do nastopa za 1 mm znižane veznice ST in čas do nastopa angine pektoris) niti pri kliničnih opazovanih dogodkih.
English: The dose is one tablet of 35mg of trimetazidine twice daily during meals.
Slovenian: Odmerek je ena tableta s 35 mg trimetazidina dvakrat dnevno med obrokom.
English: Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
Slovenian: Trimetazidin je pri odraslih bolnikih indiciran kot dodatno zdravilo za simptomatsko zdravljenje bolnikov s stabilno angino pektoris, pri katerih z zdravili prve izbire te bolezni ni mogoče zadovoljivo nadzorovati oziroma bolniki zdravljenja z njimi ne prenašajo.
English: Arterial Hypotension , Orthostatic hypotension that may be associated with malaise, dizziness or fall, in particular in patients taking antihypertensive treatment, flushing
Slovenian: Žilne bolezni redki arterijska hipotenzija, ortostatska hipotenzija, ki je lahko povezana s splošnim slabim počutjem, omotico ali padcem, zlasti pri bolnikih, zdravljenih z antihipertenzivi, zardevanje
English: If you get any side effects, talk to your doctor or pharmacist.
Slovenian: Če ste negotovi, se posvetujte s svojim zdravnikom ali s farmacevtom.
English: Patients with renal impairment
Slovenian: Bolniki z ledvično okvaro:
English: In a 426-patients randomized, double blind, placebo-controlled study (TRIMPOL-II), trimetazidine (60mg/day) added to metoprolol 100mg daily (50 mg b.i.d) for 12 weeks significantly improved statistically exercise tests parameters and clinical symptoms as compared to placebo: total exercise duration +20.1s, p= 0.023, total workload +0.54 METs, p=0.001, time to 1-mm ST-segment depression +33.4s, p=0.003, time to onset of angina +33.9s, p<0.001, angina attacks/week -0.73, p=0.014 and short acting nitrates consumption/week, -0.63, p=0.032, without hemodynamic changes.
Slovenian: V randomizirani, dvojno slepi, s placebom nadzorovani študiji pri 426 bolnikih (TRIMPOL-II) je trimetazidin (60 mg/dan) poleg metoprolola v odmerku 100 mg dnevno (50 mg dvakrat dnevno) v 12 tednih statistično značilno izboljšal parametre obremenitvenih testov in klinične simptome v primerjavi s placebom: trajanje celotne vadbe +20,1 s, p = 0,023, skupna obremenitev +0,54 MET, p = 0,001, čas do nastopa za 1 mm znižane veznice ST +33,4 s, p = 0,003, čas do nastopa angine pektoris +33,9 s, p < 0,001, število anginoznih napadov/teden -0,73, p = 0,014, in poraba kratko delujočih nitratov/teden, -0,63, p = 0,032, brez hemodinamičnih sprememb.
English: Elderly patients may have increased trimetazidine exposure due to age-related decrease in renal function (see section 5.2).
Slovenian: Pri starejših bolnikih je zaradi s starostjo povezanega zmanjšanega delovanja ledvic izpostavljenost trimetazidinu lahko večja (glejte poglavje 5.2).
English: What you need to know before you take <invented name> Do not take <invented name> - if you are allergic to trimetazidine or any of the other ingredients of this medicine (listed in section - if you have a Parkinson disease: disease of the brain affecting movement (trembling, rigid posture,
Slovenian: Ne jemljite zdravila <Izmišljeno ime> - če ste alergični na trimetazidin ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če imate Parkinsonovo bolezen: bolezen možganov, ki vpliva na gibanje (tresenje, okorela drža, počasni gibi in negotova, neuravnotežena hoja), - če imate hude težave z ledvicami.
English: The occurrence of movement disorders such as parkinsonian symptoms, restless leg syndrome, tremors, gait instability should lead to definitive withdrawal of trimetazidine.
Slovenian: V primeru pojava motenj gibanja, kot so simptomi Parkinsonove bolezni, sindrom nemirnih nog, tremor, nestabilna hoja, je treba zdravljenje s trimetazidinom dokončno ukiniti.
English: What <invented name>is and what it is used for This medicine is intended for use in adult patient, in combination with other medicines to treat angina pectoris (chest pain caused by coronary disease).
Slovenian: To zdravilo je pri odraslih bolnikih skupaj z drugimi zdravili namenjeno za zdravljenje angine pektoris (bolečine v prsih, ki jo povzroča koronarna bolezen).
English: Palpitations, extrasystoles, tachycardia
Slovenian: Srčne bolezni redki palpitacije, ekstrasistole, tahikardija
English: This medicine can cause or worsen symptoms such as trembling, rigid posture, slow movements and a shuffling, unbalanced walk, especially in elderly patients, which should be investigated and reported to your doctor who could reassess the treatment.
Slovenian: To zdravilo lahko povzroči ali poslabša simptome, kot so tresenje, okorela drža, počasni gibi in negotova, neuravnotežena hoja, zlasti pri starejših bolnikih.
English: In a 1962 patients three-month randomised, double-blinded study (Vasco study) on top of atenolol 50 mg/d, two dosages of trimetazidine (70 mg/d and 140 mg/d) were tested versus placebo.
Slovenian: V randomizirani, dvojno slepi trimesečni študiji pri 1962 bolnikih (študija VASCO) so dve odmerjanji trimetazidina (70 mg/dan in 140 mg/dan) poleg atenolola 50 mg/dan primerjali s placebom.
English: The recommended dose of <invented name> 35mg is one tablet to be taken two times a day during meals in the morning and evening.
Slovenian: Priporočeni odmerek zdravila <Izmišljeno ime> 35 mg je ena tableta dvakrat na dan med obrokom, zjutraj in zvečer.
English: However, in the subgroup of symptomatic patients (n= 1574) defined in a post-hoc analysis, trimetazidine (140 mg) significantly improved total exercise duration (+23.8 s versus +13.1 s placebo; p=0.001) and time to onset of angina (+46.3 s versus +32.5 s placebo; p=0.005).
Slovenian: Kljub temu je trimetazidin (140 mg) pri podskupini simptomatskih bolnikov (n=1574), določeni v naknadni analizi, značilno izboljšal trajanje celotne vadbe (+23,8 s v primerjavi s +13,1 s pri placebu; p=0,001) in čas do nastopa angine pektoris (+46,3 s v primerjavi s +32,5 s pri placebu; p=0,005).
English: Driving and using machines
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
English: Sleep disorders (insomnia, drowsiness)
Slovenian: Bolezni živčevja neznana pogostnost motnje spanja (nespečnost, zaspanost)
English: In patients with ischaemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels.
Slovenian: Trimetazidin pri bolnikih z ishemično boleznijo srca deluje na presnovo celic srčne mišice in v njih ohranja visoko raven energetsko bogatih fosfatov.
English: 4.3 Contraindications [the currently approved contraindications should be deleted and replaced by the following]
Slovenian: [trenutno odobrene kontraindikacije je treba izbrisati ter jih nadomestiti z naslednjimi]
English: Trimetazidine can cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), which should be regularly investigated, especially in elderly patients.
Slovenian: Trimetazidin lahko povzroči ali poslabša simptome Parkinsonove bolezni (tremor, akinezijo, hipertonijo).
English: B. Package Leaflet
Slovenian: B. Navodilo za uporabo
English: Acute generalized exanthematus pustulosis (AGEP), angioedema
Slovenian: Bolezni kože in podkožja neznana pogostnost akutna generalizirana eksantematozna pustuloza (AGEP), angioedem
English: The dose is one tablet of 20mg or 1 ml (20 drops) of oral drop solution of trimetazidine three times a day during meals.
Slovenian: Odmerek je ena tableta z 20 mg trimetazidina ali 1 ml (20 kapljic) peroralne raztopine trimetazidina trikrat dnevno med obrokom.
English: The recommended dose of <invented name> 20mg/ml solution is 20 drops to be taken three times a day during meals.
Slovenian: Priporočeni odmerek zdravila <Izmišljeno ime> 20 mg/ml raztopina je 20 kapljic trikrat na dan med obrokom.
English: No significant difference between groups could be found for the other secondary endpoints (total exercise duration, total workload and clinical endpoints).
Slovenian: Za druge sekundarne opazovane dogodke (trajanje celotne vadbe, skupno obremenitev in klinične opazovane dogodke) med skupinama niso našli značilnih razlik.
English: Parkinsonian symptoms (tremor, akinesia, hypertonia), gait instability, restlessleg syndrome, other related movement disorders, usually reversible after treatment discontinuation
Slovenian: Prednostni izraz omotica, glavobol neznana pogostnost simptomi Parkinsonove bolezni (tremor, akinezija, hipertonija), nestabilna hoja, sindrom nemirnih nog, druge podobne motnje gibanja, simptomi so običajno reverzibilni po prekinitvi zdravljenja
English: The recommended dose of <invented name> 20mg is one tablet to be taken three times a day during meals.
Slovenian: Priporočeni odmerek zdravila <Izmišljeno ime> 20 mg je ena tableta trikrat na dan med obrokom.
English: Talk to your doctor or pharmacist before taking <invented name>
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo <Izmišljeno ime>
English: In patients with moderate renal impairment (creatinine clearance [30-60] ml/min) (see sections 4.4 and 5.2), the recommended dose is 1 tablet of 35mg in the morning during breakfast.
Slovenian: Pri bolnikih z zmerno ledvično okvaro (očistek kreatinina 30 - 60 ml/min) (glejte poglavji 4.4 in 5.2) je priporočeni odmerek 1 tableta s 35 mg trimetazidina zjutraj med zajtrkom.
English: In patients with moderate renal impairment (creatinine clearance [30-60] ml/min), the recommended dose is 1 tablet of 35mg in the morning during breakfast.
Slovenian: Pri bolnikih z zmerno ledvično okvaro (očistek kreatinina 30 - 60 ml/min) je priporočeni odmerek 1 tableta s 35 mg trimetazidina zjutraj med zajtrkom.
English: In patients with moderate renal impairment (creatinine clearance [30-60] ml/min) (see sections 4.4 and 5.2), the recommended dose is 1 tablet of 20mg or 1 ml (20 drops) of oral drop solution twice daily, i.e., one in the morning and one in the evening during meals.
Slovenian: Pri bolnikih z zmerno ledvično okvaro (očistek kreatinina 30 - 60 ml/min) (glejte poglavji 4.4 in 5.2) je priporočeni odmerek 1 tableta z 20 mg trimetazidina ali 1 ml (20 kapljic) peroralne raztopine trimetazidina dvakrat dnevno, t.j.
English: In patients with moderate renal impairment (creatinine clearance [30-60] ml/min), the recommended dose is 1 tablet of 20mg or 1 ml (20 drops) of oral drop solution twice daily, i.e., one in the morning and one in the evening during meals.
Slovenian: Pri bolnikih z zmerno ledvično okvaro (očistek kreatinina 30 - 60 ml/min) je priporočeni odmerek 1 tableta z 20 mg trimetazidina ali 1 ml (20 kapljic) peroralne raztopine trimetazidina dvakrat dnevno, t.j.
English: Dizziness, headache, abdominal pain, diarrhoea, indigestion, feeling sick, vomiting, rash, itching, hives and feeling of weakness.
Slovenian: Bolezni prebavil bolečine v trebuhu, diareja, dispepsija, navzea in bruhanje neznana pogostnost zaprtje pogosti izpuščaj, pruritus, urtikarija
English: - Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders, - Severe renal impairment (creatinine clearance < 30ml/min).
Slovenian: - Parkinsonova bolezen, simptomi Parkinsonove bolezni, tremor, sindrom nemirnih nog in druge podobne motnje gibanja.
English: Agranulocytosis Thrombocytopenia Thrombocytopenic purpura
Slovenian: Bolezni krvi in limfatičnega sistema neznana pogostnost agranulocitoza trombocitopenija trombocitopenična purpura